Michael J Tolentino

This inventor holds 15 USPTO granted patents, plus 2 CIPO patents and 4 EPO patents. Top assignees: University of Pennsylvania, The Trustees of the University of Pennyslvania. Active years: 2006-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael J Tolentino. Retrieved from https://idiyas.com/inventor/michael-j-tolentino

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15

% Patents Active = 26.7

CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 2.1

ph-index = 6

Forward Citations = 287(Granted Patents)

Location History:

Lakeland, FL (US) (2010 - 2012)
Villanova, PA (US) (2006 - 2015)
Winter Haven, FL (US) (2015)

Company Filing History:

14 out of 2,659

University of Pennsylvania

patents

1 out of 5

The Trustees of the University of Pennyslvania

patents

Years Active: 2006-2015

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9150863 - Compositions and methods for siRNA inhibition of angiogenesis (2015-10-06),

2. 8946403 - Compositions and methods for siRNA inhibition of angiogenesis (2015-02-03),

3. 8546345 - Compositions and methods for siRNA inhibition of angiogenesis (2013-10-01),

4. 8541384 - Compositions and methods for siRNA inhibition of angiogenesis (2013-09-24),

5. 8236775 - Compositions and methods for siRNA inhibition of HIF-1 α (2012-08-07),

6. 8193163 - Compositions and methods for siRNA inhibition of ICAM-1 (2012-06-05),

7. 7994305 - Compositions and methods for siRNA inhibition of angiopoietin 1 and 2 and their receptor Tie2 (2011-08-09),

8. 7847090 - Compositions and methods for siRNA inhibition of ICAM-1 (2010-12-07),

9. 7807814 - Compositions and methods for combined therapy of disease (2010-10-05),

10. 7750143 - Compositions and methods for siRNA inhibition of angiogenesis (2010-07-06),

11. 7674895 - Compositions and methods for siRNA inhibition of angiogenesis (2010-03-09),

12. 7645744 - Compositions and methods for siRNA inhibition of HIF-1 alpha (2010-01-12),

13. 7521431 - Compositions and methods for siRNA inhibition of HIF-1 alpha (2009-04-21),

14. 7345027 - Compositions and methods for siRNA inhibition of angiogenesis (2008-03-18),

15. 7148342 - Compositions and methods for sirna inhibition of angiogenesis (2006-12-12),

Title: Michael J Tolentino: Innovator in RNA Interference and Angiogenesis Inhibition

Introduction

Michael J Tolentino is a prominent inventor based in Villanova, PA (US). He has made significant contributions to the field of RNA interference, particularly in the inhibition of angiogenesis. With a total of 15 patents, his work has the potential to impact the treatment of various diseases.

Latest Patents

Tolentino's latest patents focus on compositions and methods for siRNA inhibition of angiogenesis. His innovative approach utilizes RNA interference with small interfering RNAs that are specific for the vascular endothelial growth factor (VEGF) gene and its receptor genes, Flt-1 and Flk-1/KDR. These methods inhibit the expression of these genes, which is crucial in treating diseases characterized by angiogenesis stimulated by the overexpression of VEGF. Conditions such as diabetic retinopathy, age-related macular degeneration, and various types of cancer can be addressed through the administration of these small interfering RNAs.

Career Highlights

Throughout his career, Tolentino has worked with esteemed institutions, including the University of Pennsylvania and The Trustees of the University of Pennsylvania. His research has garnered attention for its potential to revolutionize treatment options for diseases linked to angiogenesis.

Collaborations

Tolentino has collaborated with notable colleagues, including Samuel Jotham Reich and Enrico Maria Surace. These partnerships have furthered his research and contributed to the advancement of his innovative work.

Conclusion

Michael J Tolentino stands out as a key figure in the field of RNA interference and angiogenesis inhibition. His contributions through his patents and collaborations continue to pave the way for new therapeutic approaches to critical health issues.

Profile summary based on public USPTO records.